Clinical trial
A Multicentre, Controlled, Randomised and Single-blind, Adaptive Phase IV Protocol to Evaluate Effectiveness and Cost-effectiveness of Pre-emptive Genotyping Strategy to Optimise Tacrolimus Dosage in a Pretransplant Chronic Kidney Disease Population Cohort
NCT06701825 is registered in ClinicalTrials.gov with Instituto de Investigación Hospital Universitario La Paz as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Controlled, Randomised and Single-blind, Adaptive Phase IV Protocol to Evaluate Effectiveness and Cost-effectiveness of Pre-emptive Genotyping Strategy to Optimise Tacrolimus Dosage in a Pretransplant Chronic Kidney Disease Population Cohort
- Lead sponsor
- Instituto de Investigación Hospital Universitario La Paz
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- June 2, 2025
- Completion date
- December 31, 2026
- Enrollment
- 114 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
immunosuppression, kidney disease, chronic, transplant recipient (kidney)